Learn About New Kidney Disease Medications

Understanding New Kidney Disease Medications and How They Work

Chronic kidney disease (CKD) affects more than 37 million American adults, according to the Centers for Disease Control and Prevention. In recent years, the medications available to treat kidney disease have expanded significantly, offering patients and doctors more options than ever before. New kidney disease medications work through different mechanisms to slow disease progression, reduce complications, and help patients maintain better kidney function over time.

The kidneys filter waste from blood and help regulate blood pressure, electrolytes, and red blood cell production. When kidney disease develops, the kidneys gradually lose this ability. Traditional medications focused mainly on managing blood pressure and protein in the urine. Newer medications take additional approaches. Some work by blocking specific pathways in the kidney that lead to scarring and damage. Others reduce inflammation or help manage complications like anemia that develop when kidneys don't function properly.

Understanding how these medications work helps patients have more informed conversations with their doctors about treatment options. Different medications may be recommended depending on the type and stage of kidney disease, other health conditions the patient has, and how their kidneys are currently functioning. A patient with type 2 diabetes and kidney disease might receive different medications than someone with kidney disease from a different cause.

The development of new kidney disease medications represents years of research into how kidney damage occurs at the cellular level. Scientists identified specific proteins and pathways that contribute to kidney scarring and disease progression. By targeting these pathways, newer medications can slow or prevent further kidney damage in ways that older medications could not. This has changed treatment approaches significantly over the past five to ten years.

Practical Takeaway: Learn the names and basic functions of any medications prescribed for kidney disease. Ask your doctor which specific kidney disease pathways the medication targets and how it differs from other available options. This knowledge helps you understand why a particular medication was chosen for your situation.

SGLT2 Inhibitors: A Major Breakthrough in Kidney Protection

SGLT2 inhibitors represent one of the most significant advances in kidney disease treatment. These medications were originally developed to treat type 2 diabetes by helping the kidneys remove excess glucose through urine. However, clinical trials revealed that these drugs provide kidney protection benefits far beyond their glucose-lowering effects. Studies show that SGLT2 inhibitors can slow kidney disease progression by 25 to 39 percent, depending on the specific medication and patient population.

Common SGLT2 inhibitors include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). These medications work by blocking a protein in the kidney that normally reabsorbs glucose back into the bloodstream. By allowing glucose to be excreted in urine, the kidneys experience less strain and damage. The medications also lower blood pressure naturally and reduce proteinuria, which is protein leakage in the urine that indicates kidney stress.

What makes SGLT2 inhibitors particularly important is that they help patients across different categories of kidney disease. People with type 2 diabetes and CKD benefit. People with CKD who don't have diabetes also show kidney protection. In 2020, the FDA approved dapagliflozin specifically for CKD regardless of diabetes status, marking a shift in how kidney disease is treated. More recently, studies have shown benefits even in patients with advanced kidney disease and reduced kidney function.

Patients taking SGLT2 inhibitors should be aware of potential side effects, which are generally mild. Genitourinary infections occur in some patients, particularly women. Dehydration can be a concern, especially in older adults or those with very advanced kidney disease. Some patients experience diabetic ketoacidosis, a serious but rare condition. Despite these considerations, the kidney protection benefits have made these medications a standard part of CKD treatment for many patients.

Practical Takeaway: If you have CKD with or without diabetes, ask your doctor whether an SGLT2 inhibitor might be suitable for you. Ensure you stay well-hydrated while taking these medications and report any signs of infection to your doctor promptly.

GLP-1 Receptor Agonists and Their Expanding Role in Kidney Care

GLP-1 receptor agonists are another class of medications that originally targeted type 2 diabetes but have shown kidney protection benefits. Medications in this class include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza), and tirzepatide (Mounjaro, Zepbound). These drugs work by mimicking glucagon-like peptide 1, a hormone that helps regulate blood sugar and appetite. Beyond blood sugar control, these medications reduce weight, lower blood pressure, and provide cardiovascular protection.

Recent research demonstrates that GLP-1 receptor agonists also slow kidney disease progression. A landmark 2023 study published in the New England Journal of Medicine showed that semaglutide reduced kidney disease progression by 24 percent in patients with type 2 diabetes. Another study examining tirzepatide showed even more impressive kidney protection results. The mechanisms appear to involve weight loss, blood pressure reduction, and direct anti-inflammatory effects on kidney tissue. For patients who are overweight or obese and have both type 2 diabetes and CKD, GLP-1 receptor agonists offer multiple health benefits simultaneously.

The side effect profile of GLP-1 receptor agonists includes nausea, vomiting, and diarrhea, particularly when first starting the medication or increasing the dose. Most patients develop tolerance to gastrointestinal side effects over time. Some patients experience dehydration or acute kidney injury if they become severely ill, stop eating, or have other complications. A small number of patients have experienced severe pancreatitis, though this remains rare. Weight loss can be significant—sometimes 15 to 20 percent of body weight over several months—which requires monitoring for nutritional adequacy.

Unlike some kidney disease medications that are limited to patients with specific types of kidney disease, GLP-1 receptor agonists can be used across different CKD etiologies. They work well in combination with SGLT2 inhibitors and other kidney protective medications. Some doctors now consider using both classes together for patients with diabetes and advancing kidney disease, as the medications work through different mechanisms and may provide additive benefit.

Practical Takeaway: If you have type 2 diabetes and CKD, particularly if you're overweight, discuss GLP-1 receptor agonists with your doctor. Be prepared for possible nausea when starting these medications, and ensure you maintain adequate nutrition and hydration, especially if you're losing weight.

Finerenone: A New Approach to Non-Diabetic Kidney Disease

Finerenone (Kerendia) represents a different approach to kidney disease treatment compared to SGLT2 inhibitors and GLP-1 receptor agonists. This medication is a nonsteroidal mineralocorticoid receptor antagonist, a complex name for a drug that blocks specific pathways leading to kidney inflammation and scarring. Finerenone was approved by the FDA in 2021 for patients with CKD and type 2 diabetes. In 2023, the FDA expanded its use to patients with CKD without diabetes, opening new treatment options for a broader patient population.

The significance of finerenone for non-diabetic kidney disease cannot be overstated. Many patients with CKD have kidney disease from causes other than diabetes—including IgA nephropathy, lupus, autoimmune diseases, or unknown causes. Before finerenone, treatment options for these patients were limited to blood pressure control and sometimes immunosuppressive medications. The clinical trial demonstrating finerenone's effectiveness in non-diabetic CKD, called FIDELIO-DKD, showed approximately 18 percent reduction in kidney disease progression in patients without diabetes.

Finerenone works by blocking the mineralocorticoid receptor, which is involved in inflammatory and fibrotic pathways that damage kidney tissue. Unlike older mineralocorticoid receptor antagonists such as spironolactone, finerenone is selective—it primarily targets kidney tissue rather than affecting electrolyte balance throughout the body. This selectivity means fewer problems with potassium levels, one of the main concerns with older medications in this class. Patients still need regular blood work to monitor potassium and kidney function,